



Company Overview

Key Statistics

(as of March 2011)

Ticker	CSBR.PK
Market Cap	\$32.42M
Share Price	\$0.88
Shares Outstanding	36.84M
Fiscal Year End	April 30

Management

David Sidransky, M.D.
Chairman

Douglas D. Burkett, PhD
President

Manuel Hidalgo, M.D., PhD
Chief Scientific Officer

James M. Martell
Chief Administrative Officer

Durwood C. Settles
Acting Chief Financial Officer

Investor Relations

The Investor Relations Group
11 Stone Street
New York, NY 10004
Tel.: (212) 825-3210
Fax: (212) 825-3229

Investor Relations
James Carbonara
Adam Holdsworth

Champions Biotechnology, Inc. is engaged in the development of advanced preclinical platforms and predictive tumor specific data to enhance and accelerate the value of oncology drugs. The Company has developed a novel preclinical platform derived from their propriety Biomerk Tumorgraft™ models that can potentially predict the outcome of Phase II clinical trials. This is an alternative approach that utilizes the implantation of primary human tumors in immune deficient mice within hours after the sample is taken from the patient. The Tumorgrafts are then propagated from the resulting xenografts in a manner that preserves the biological properties of the original human tumor. Biomerk Tumorgrafts are passaged only a few times and never in tissue culture and thus differ from traditional xenograft models. The Company believes that these Tumorgrafts closely reflect human cancer biology and their response to drugs is more predictive of clinical outcomes in cancer patients. The Company leverages their preclinical platform to evaluate drug candidates and to develop a portfolio of novel therapeutic candidates through pre-clinical trials. The predictive platform and tumor specific data are also offered to physicians for personalized patient care and to companies for preclinical evaluation of drug candidates in models that integrate prognostic testing with biomarker discovery.

Investment Highlights

- Champions novel preclinical platform addresses many of the issues described in FDA's Critical Path reports
- Validation that the Company's preclinical platform predicts Phase II clinical outcomes may make it a highly valued standard for the industry; the Company's goal is to generate future royalty arrangements
- Champions preclinical platform may provide the Company with a unique advantage in the selection of high potential oncology drug candidates for in licensing, co development or acquisition
- Champions preclinical platform enables the discovery of biomarkers that may facilitate shorter, less expensive clinical development with a greater probability of regulatory success
- The Company's own drug candidates may dramatically increase in value if testing in its predictive preclinical platform shows promising results and results in discovery of valuable biomarkers

Technology Platform

Biomerk Tumorgrafts™

Biomerk Tumorgrafts are an alternative approach derived from tumors transplanted directly from human patients into mice. As these unique xenografts grow in the test animal, the characteristics of the original human cancer are preserved.

- Less than ten passages; never passaged in tissue culture
- Maintain the fundamental genotypic features of the original cancer
- Represent the genetic heterogeneity of the cancer
- Predict the effectiveness of chemotherapeutic drugs in patients
- Potentially predict the outcome of Phase II clinical trials

An additional potential benefit of the Biomerk Tumorgraft preclinical platform is that it may be used to integrate prognostic testing with biomarker discovery. Biomarkers enable:

- The identification of drug(s) most likely to be effective against specific tumor types and patients that are most likely to benefit from specific drugs
- Accelerated and lower cost clinical trials with improved probability of regulatory success through evaluation of the optimal patient population for the drug(s) being evaluated

Primary Emphasis

Accelerated Drug Development

Champions Biotechnology's primary emphasis is to use its BiomerK Tumorgraft preclinical platform to evaluate early stage oncology drug candidates and to identify those drugs with high potential that the Company may wish to acquire or partner to develop.

As drugs progress through this early stage of development, the Company plans to sell, partner or license them to pharmaceutical and/or biotechnology companies, as appropriate. This strategy is expected to enable the Company to leverage the competencies of these partners or licensees to maximize the Company's return on investment in a relatively short time frame.

The ability to test and predict which early stage drug candidates have the best chance to succeed in human clinical trials is of profound value and benefit to the Company's drug development program as it seeks drug partnerships and acquisitions to expand its oncology drug pipeline. Champions' goal is to leverage the unique value of BiomerK Tumorgrafts to generate future revenues through royalty arrangements, partnerships, and acquisitions.

The Company is currently evaluating a number of potential drug candidates and has already acquired the patent rights for two Benzoylphenylurea (BPU) sulfur analog compounds (SG410 and SG430) with promising in vivo and in vitro activity against prostate and pancreatic cancer. These compounds are anti-miotoxic inhibitors that target microtubule associated protein tau (MAPT) deficient tumors. The Company has begun preclinical development of the most promising candidate, SG410 and plans to evaluate its efficacy in BiomerK Tumorgraft models. If results are promising the Company plans to complete preclinical development and then sell, partner or license SG410 for its remaining clinical development.

Synergistic Services

The Company operates two synergistic businesses that assist in building and growing the value of its BiomerK Tumorgraft preclinical platform and oncology drug pipeline.

Personalized Oncology:

The Company assists physicians by maximizing personalized treatment options for their cancer patients through access to expert medical information panels and tumor specific data.

The Company administers expert medical panels with world renown participants that are selected based on the patient's specific cancer type and condition. The panel's goal is to assist the physician by: (i) analyzing prior medical records and test results, (ii) assisting in evaluating both conventional and novel research and treatment options, and (iii) recommending specialized testing, analysis and interpretation of data from the patient's cancer tissues, if appropriate.

Physicians may also have the opportunity to arrange development of Personalized Tumorgrafts from their patient's tumor. Development of the Personalized Tumorgrafts enables extensive in vivo testing of numerous novel and standard drugs and drug combinations. This targeted process typically provides data regarding the drug/drug combinations that are the least and most effective. Personalized Tumorgrafts may also enable the development of a Personalized Vaccine.

Preclinical eValuation:


Champions offers the benefits of its Preclinical Platform to pharmaceutical and biotechnology companies. Studies using BiomerK Tumorgrafts have been shown to be predictive of how drugs perform in clinical settings. These results may be critical in appropriately designing Phase I and Phase II clinical trials. The Preclinical eValuation may enable companies to assign and enhance value of:

- Novel oncology drug candidates
- Promising drugs that failed traditional studies
- Marketed drugs through evaluation of new, targeted applications

An additional benefit of the platform is that BiomerK Tumorgrafts may be used to integrate drug screening with biomarker discovery. Biomarker discovery enables:

- Development of companion diagnostic tests to identify the specific patients that are most likely to benefit from each drug
- Faster and less expensive clinical development plans and an improved likelihood of regulatory and market success

Champions performs testing in its BiomerK Tumorgrafts on a fee for service basis with a goal to generate royalty arrangements in select agreements.



Disclaimer: The information disseminated by the Investor Relations Group ("IRG," us or we") is for information purposes only and is neither a solicitation to buy nor an offer to sell securities. We do not undertake or purport to render any investment advice or recommendations for the buying and selling of securities. Companies that are profiled may have engaged our services to perform investor relations services including promotional services and the placement of the profiled companies on our website. IRG compensation for such services has been or will be made in cash and in the form of securities of the profiled company. The amount of any compensation is available upon request. We may liquidate any securities that we receive as compensation when deemed appropriate to do so. The assembled information herein is based on information supplied by the company, press releases, SEC filings or from other sources believed to be reliable as of the date of the report on the featured companies but no representation is expressed or implied as to its accuracy, completeness or correctness. It is subject to change without notice. IRG and its affiliates do not claim to be brokers, broker-dealers, market makers, investment bankers, advisors, analysts or underwriters in information materials, Fact Sheets and other forms of informational media provided by us. We do not contain forward-looking statements as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Forward-looking statements are subject to a number of known and unknown risks and uncertainties outside our control that could cause actual operations or results to differ materially from those anticipated. The cautionary statements made herein should be read as being applicable to all related forward-looking statements wherever they appear on this site or in other communications. We encourage you to visit the Securities Exchange Commission website at <http://www.sec.gov>.